Norway· NO-ID_3CF0EC0B-4900-4BAC-AF52-B53475AC9F89
Ogivri
A trastuzumab product containing trastuzumab, registered in Norway by Biosimilar Collaborations. The same ATC class is registered in 14 of our 19 countries.
Checked against FEST (Norway) on
Informational only — not a medical device.
Where it is registered
Trastuzumab is registered in 14 of 19 countries.
Countries holding a registration under ATC L01FD01 (trastuzumab), each read from that country’s own register.
- This record: Norway, from FEST (Norway)
- 8 of them publish a price we can compare per daily dose
Trastuzumab · ATC L01FD01
14 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Japan
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of trastuzumab costs, country by country.
Normalised to the WHO defined daily dose (28.6 mg), so markets compare like for like.
- 1 market with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Trastuzumab · price per daily dose (28.6 mg)
USD · FX 28 Sept 2026
- CH Switzerland$116.57
The record
At a glance
FEST (Norway)- Active substance
- Trastuzumab
- Manufacturer
- Biosimilar Collaborations
- Country
- Norway (NO)
- ATC code
- L01FD01
- ATC class
- Trastuzumab
- Defined daily dose
- 28.6 mg, P
- Reimbursed
- Not published by this register
- Source register
- FEST (Norway)
- Last checked
- September 25, 2026
Packs & prices · 3
- no_merkevare_idID_3CF0EC0B-4900-4BAC-AF52-B53475AC9F89
- no_varenummer214782150
- gtin3837000184570
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
81 interactions on record for trastuzumab.
Graded by severity as the source publishes them — 34 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Trastuzumab · interactions on record
81 records
- 34 severe
- 47 moderate
Most severe, free to view
- CladribineL01BB04severe
- DoxorubicinL01DB01severe
- DaunorubicinL01DB02severe
- EpirubicinL01DB03severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Trastuzumab in 15 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- FinlandDazublysCuraTeQ Biologics (Malta) Limited
- CzechiaDAZUBLYSCuraTeQ Biologics (Malta) Limited, Floriana
- BelgiumDazublys 150 mgCuraTeQ Biologics (Malta)
- IcelandDazublysCuraTeQ Biologics (Malta) Limited
- PolandDazublysCuraTeQ Biologics s.r.o.
- SwedenDazublys 150 mg Pulver till koncentrat till infusionsvätska, lösningCuraTeQ Biologics (Malta) Limited
- IrelandDazublys 150 mg powder for concentrate for solution for infusionCurateq Biologics s.r.o.
- SpainHERCEPTIN 150 mg POLVO PARA CONCENTRADO PARA SOLUCION PARA PERFUSIONRoche Registration Gmbh
Authorised across Europe · EMA
The same active substance is authorised in 2 EEA countries. Names it is sold under:
- Iceland · Dazublys, Herceptin
- Liechtenstein · Dazublys, Herceptin
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FEST (Norway). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/968c31fa-ff32-4c9b-addf-93f4eb776d9c GET /v1/drugs/968c31fa-ff32-4c9b-addf-93f4eb776d9c?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Pulver til konsentrat til infusjonsvæske, oppløsning",
"source": "fest",
"status": "A",
"atc_name": "Trastuzumab",
"merkevare_id": "ID_3CF0EC0B-4900-4BAC-AF52-B53475AC9F89",
"name_form_strength": "Ogivri pulv til kons til inf væske, oppl 150 mg",
"prescription_group": "C"
}See everything about trastuzumab.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.